Seeking Alpha

Amicus Therapeutics (FOLD) +9.6% premarket after it says a preliminary study of its treatment...

Amicus Therapeutics (FOLD) +9.6% premarket after it says a preliminary study of its treatment for Pompe disease showed positive results; AT2220-enzyme replacement therapy co-administration increased pompe enzyme activity in first three dose cohorts in the phase 2 study.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|